No biomarker
|
Giant Cell Tumor of Bone
|
No biomarker
|
Giant Cell Tumor of Bone
|
denosumab Sensitive: A1 - Approval
|
denosumab Sensitive: A1 - Approval
|
No biomarker
|
Tenosynovial Giant Cell Tumor
|
No biomarker
|
Tenosynovial Giant Cell Tumor
|
pexidartinib Sensitive: A1 - Approval
|
pexidartinib Sensitive: A1 - Approval
|
No biomarker
|
Chordoma
|
No biomarker
|
Chordoma
|
sorafenib Sensitive: A2 - Guideline
|
sorafenib Sensitive: A2 - Guideline
|
No biomarker
|
Chordoma
|
No biomarker
|
Chordoma
|
dasatinib Sensitive: A2 - Guideline
|
dasatinib Sensitive: A2 - Guideline
|
No biomarker
|
Chordoma
|
No biomarker
|
Chordoma
|
YD312 Sensitive: A2 - Guideline
|
YD312 Sensitive: A2 - Guideline
|
No biomarker
|
Chordoma
|
No biomarker
|
Chordoma
|
sunitinib Sensitive: A2 - Guideline
|
sunitinib Sensitive: A2 - Guideline
|
No biomarker
|
Chordoma
|
No biomarker
|
Chordoma
|
erlotinib Sensitive: A2 - Guideline
|
erlotinib Sensitive: A2 - Guideline
|
TMB-H
|
Chordoma
|
TMB-H
|
Chordoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
EGFR expression
|
Chordoma
|
EGFR expression
|
Chordoma
|
lapatinib Sensitive: A2 - Guideline
|
lapatinib Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Chordoma
|
MSI-H/dMMR
|
Chordoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Chordoma
|
No biomarker
|
Chordoma
|
imatinib Sensitive: A2 - Guideline
|
imatinib Sensitive: A2 - Guideline
|
No biomarker
|
Tenosynovial Giant Cell Tumor
|
No biomarker
|
Tenosynovial Giant Cell Tumor
|
nilotinib Sensitive: A2 - Guideline
|
nilotinib Sensitive: A2 - Guideline
|
SMARCB1 negative
|
Chordoma
|
SMARCB1 negative
|
Chordoma
|
tazemetostat Sensitive: C2 – Inclusion Criteria
|
tazemetostat Sensitive: C2 – Inclusion Criteria
|
PIK3CA amplification
|
Chordoma
|
PIK3CA amplification
|
Chordoma
|
everolimus Sensitive: C3 – Early Trials
|
everolimus Sensitive: C3 – Early Trials
|
PIK3CA M1043I
|
Chordoma
|
PIK3CA M1043I
|
Chordoma
|
everolimus Sensitive: C3 – Early Trials
|
everolimus Sensitive: C3 – Early Trials
|
PTEN deletion
|
Chordoma
|
PTEN deletion
|
Chordoma
|
PDGFR inhibitor Resistant: C4 – Case Studies
|
PDGFR inhibitor Resistant: C4 – Case Studies
|
PTEN deletion
|
Chordoma
|
PTEN deletion
|
Chordoma
|
PDGFR inhibitor + HDAC inhibitor Sensitive: C4 – Case Studies
|
PDGFR inhibitor + HDAC inhibitor Sensitive: C4 – Case Studies
|
H3F3A mutation + ARID2 mutation
|
Giant Cell Tumor of Bone
|
H3F3A mutation + ARID2 mutation
|
Giant Cell Tumor of Bone
|
denosumab Resistant: C4 – Case Studies
|
denosumab Resistant: C4 – Case Studies
|
COL6A3-CSF1 fusion
|
Tenosynovial Giant Cell Tumor
|
COL6A3-CSF1 fusion
|
Tenosynovial Giant Cell Tumor
|
gefitinib + mitoxantrone Sensitive: C4 – Case Studies
|
gefitinib + mitoxantrone Sensitive: C4 – Case Studies
|
SMARCB1 deletion
|
Chordoma
|
SMARCB1 deletion
|
Chordoma
|
nivolumab Sensitive: C4 – Case Studies
|
nivolumab Sensitive: C4 – Case Studies
|
AXL underexpression
|
Chordoma
|
AXL underexpression
|
Chordoma
|
afatinib Sensitive: D – Preclinical
|
afatinib Sensitive: D – Preclinical
|
STK33 underexpression
|
Chordoma
|
STK33 underexpression
|
Chordoma
|
afatinib Sensitive: D – Preclinical
|
afatinib Sensitive: D – Preclinical
|
PBRM1 mutation
|
Chordoma
|
PBRM1 mutation
|
Chordoma
|
tazemetostat Sensitive: D – Preclinical
|
tazemetostat Sensitive: D – Preclinical
|